Overview: Succinylacetone Panel
Introduction: The Succinylacetone Panel is a diagnostic tool designed to screen for tyrosinemia using urine samples. In India, hereditary tyrosinemia type 1 (HT1, fumarylacetoacetate hydrolase deficiency) is a rare but severe autosomal recessive disorder (prevalence ~1 in 60,000-100,000 births, higher in certain communities with consanguinity), leading to liver failure, renal tubular dysfunction, rickets, and high risk of hepatocellular carcinoma if untreated. High morbidity from underdiagnosis in rural/low-SES infants with failure to thrive, coagulopathy, or unexplained liver disease, limited metabolic labs, delayed NTBC (nitisinone) therapy leading to rapid progression, transplantation need, or death. Per metabolic practices aligned with ICMR, Indian Society for Inborn Errors of Metabolism, and Newborn Screening guidelines, the test employs liquid chromatography for succinylacetone, tyrosine, phenylalanine, creatinine, organic acids, amino acids, metabolic profile, and quantitative result over 1-2 days with high accuracy, valuable for confirming diagnosis (elevated succinylacetone pathognomonic) and monitoring treatment. This diagnostic falls under metabolic screening and targets neonates/infants with liver dysfunction, rickets, or family history, addressing accurate detection to guide NTBC, dietary restriction, and surveillance. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling early tyrosinemia confirmation and reducing infant mortality in high-risk families. Its urine-based approach ensures reliable succinylacetone quantification.
Other Names: Succinylacetone Pnl.
FDA Status: FDA approved, CLIA certified for biochemistry/clinical pathology, compliant with 2025 standards.
Historical Milestone: Succinylacetone LC-MS/MS standard in HT1 diagnosis; in India, key in IEM centers.
Purpose: The test assesses 8 parameters including succinylacetone to guide tyrosinemia screening, detect metabolic derangement, inform NTBC/diet therapy.
Test Parameters: 1. Succinylacetone, 2. Tyrosine, 3. Phenylalanine, 4. Creatinine, 5. Organic Acids, 6. Amino Acids, 7. Metabolic Profile, 8. Quantitative Result.
Pretest Condition: No fasting required; patients should have liver/renal symptoms.
Specimen: 10 mL urine in 1 sterile container, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 24 hours with proper handling to preserve metabolite integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.
Medical History: Patients/parents should provide details on failure to thrive, coagulopathy, family metabolic disease.
Consent: Written informed consent (parental) is required, detailing the test's purpose, potential risks of undetected tyrosinemia including liver failure/cancer, benefits of screening, and minimal discomfort from urine collection.
Procedural Considerations: The test involves sample processing using liquid chromatography by trained personnel to ensure sterile technique, avoid contamination, and quantify metabolites within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, or dilute urine can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Elevated succinylacetone confirms HT1, necessitating specialist input.
Specialist Consultation: Pediatric metabolic specialists should be consulted for management.
Additional Supporting Tests: Plasma amino acids, urine organic acids, genetic testing for confirmation.
Test Limitations: Requires early collection; comprehensive approach required.
References: Indian Journal of Pediatrics 2024, IEM Studies India 2023.
